Imitates a medicine
Packaging, brand, device or batch details are presented as genuine when they are not. The contents may include the named active substance and still be falsified.
Incident record · O-041
Counterfeit and unauthorised GLP-1-type products
Counterfeits are documented, not hypothetical. Regulators have found falsified pens, copied batch references, fraudulent labels and illicit production. Each incident proves only what the investigation established.
Counterfeit GLP-1 products have entered online and regulated-looking supply channels. An unauthorised vial may use a research label, while a counterfeit imitates an approved medicine. Both can leave identity, quantity, sterility, storage and manufacturer accountability unresolved. Packaging inspection helps, but it cannot replace product verification.
Act on symptoms before investigating the pack
Severe, persistent abdominal pain that may spread to the back, with or without nausea or vomiting, needs urgent medical help. Use NHS 111, A&E or 999 as appropriate. For sudden or rapidly worsening eyesight, seek urgent assessment.
Counterfeit, unauthorised and diverted are different findings
Precise labels matter because the evidence and reporting route change.
No marketing authorisation
A vial or pen is sold as a treatment without the authorisation, quality system and product information required for that medicine.
Genuine product, wrong route
A genuine medicine may be stolen, mishandled or resold outside the accountable supply chain. Authenticity does not restore a missing storage history.
Documented incident ledger
Date, jurisdiction, presented product, finding and response stay on one line. We do not turn an incident into a prevalence estimate.
| Date and jurisdiction | Presented product | Finding | Regulator response | What remains unknown |
|---|---|---|---|---|
| June 2024, UK and other countries | Ozempic pens | WHO issued an alert about falsified semaglutide products detected in Brazil, the UK and the United States. | National regulators investigated and removed affected products. | The alert does not quantify all counterfeit circulation or characterise every online pen. |
| October 2025, UK | Retatrutide and tirzepatide-labelled pens | MHRA seized more than 2,000 unlicensed pens at a suspected illicit production facility. | Criminal investigation and seizure. | The public notice did not provide a product-by-product analytical table. |
| December 2025, United States | Ozempic pens using a genuine lot number | FDA seized counterfeit units distributed outside Novo Nordisk’s authorised supply chain. | Public warning and investigation. | A valid-looking lot number alone could not distinguish the counterfeit. |
| February 2026, UK | Mounjaro KwikPen | MHRA confirmed a falsified pen supplied through one online pharmacy. Tirzepatide was detected, but sterility could not be confirmed. | Batch-specific alert, patient advice and investigation. | Ingredient identity did not establish authorised manufacture, sterility or the full product specification. |
| May 2026, UK | Unlicensed weight-loss medicines | MHRA dismantled a suspected illicit manufacturing and distribution operation in its largest seizure of this kind. | Arrests, seizure and ongoing investigation. | Scale of seizure does not establish national prevalence. |
What a regulator finding can establish
A regulator may inspect packaging, query serialisation records, trace a supply route, test an active substance, measure quantity or examine microbiological quality. Public alerts often report only the findings needed for immediate action.
Absence from the alert is not a passing result. If sterility, endotoxin or impurities are not reported, they remain unreported. The same applies to harms. “No reported harm in the notice” is not evidence that nobody was harmed.
Read how contamination and mislabelling change what is in the vial.
Why visual checks have a ceiling
Spelling errors, poor print, missing information, altered device parts and implausible seller claims are useful warnings. Sophisticated copies can reproduce genuine batch numbers and packaging elements.
01
Check the route
Prescription-only medicines need a prescription and a registered pharmacy.
02
Check the pack
Look for damage, inconsistencies and unexpected presentation, without treating appearance as proof.
03
Preserve evidence
Keep packaging, photos, seller details, receipts and correspondence if safe.
04
Report
Use the MHRA route for suspicious sellers and the Yellow Card route for suspected medicine problems.
Do not taste, inject, mix or otherwise use a suspect product to “test” it. Do not send an unknown injectable through ordinary post without checking the receiving laboratory’s instructions and legal requirements.
How to read Yellow Card reports and news coverage
Yellow Card reports are suspicions submitted to help detect safety signals. A report can involve a known adverse effect, an underlying illness, another medicine, a medication error, misuse or an unverified product. It may also contain incomplete information.
A reported fatal outcome is serious and deserves investigation. It does not by itself prove that a GLP-1 medicine caused the death. Report counts also cannot give an incidence rate without reliable exposure and case verification. The MHRA assesses reports with clinical, observational and product evidence before changing guidance.
The strengthened January 2026 pancreatitis warning is a useful example. The MHRA reviewed reports and other evidence, then updated product information and public advice. It still describes Yellow Card reports as suspected associations, not proven individual causation.
A counterfeit record does not make grey-market supply uniform
Some products openly use “research” labels. Others imitate approved packs. Some may contain the named substance; others may not. The correct conclusion is not that every item is identical. It is that the supply route has lost the assurances needed to know which product is in hand.
See how the two supply routes differ, then use the compound records for semaglutide and tirzepatide.
Source ledger
Primary regulator sources checked on 7 August 2026.
- WHO Medical Product Alert No. 2/2024 · falsified Ozempic detected in Brazil, the UK and the United States.
- MHRA: falsified Mounjaro KwikPen · UK batch-specific alert, 24 February 2026.
- FDA: counterfeit Ozempic units · US seizure and lot-number warning, 5 December 2025.
- MHRA illicit production seizure · unlicensed retatrutide and tirzepatide products, October 2025.
- MHRA Yellow Card · suspected side-effect and medicine-problem reporting.
Editorial method: We record only the incident findings published by the named authority. We label unreported attributes as unreported, and we do not calculate prevalence from selected enforcement cases.
Use the right reporting route
Seller or productReport an illegal sellerPreserve the listing, payment and product details that support an investigation.
Medicine problemSubmit a Yellow CardReport a suspected side effect, defective product or counterfeit concern.
Decision aidHow the two supply routes differCompare the assurances that exist before an incident occurs.
Questions people ask
Can a counterfeit pen contain the real active ingredient?
Yes. The MHRA’s 2026 falsified Mounjaro incident detected tirzepatide, yet sterility and authorised manufacture could not be confirmed. A counterfeit remains falsified even when one expected ingredient is present.
Does a genuine batch number prove a GLP-1 pen is genuine?
No. Counterfeiters can copy genuine identifiers. The FDA’s 2025 Ozempic warning involved counterfeit units labelled with a lot number that was also authentic. Supply route, serialisation and manufacturer or regulator checks may be needed.
Do Yellow Card death reports prove GLP-1 medicines caused the deaths?
No. The reports are suspected associations used for signal detection. They do not establish causation or incidence on their own. Regulators examine case details, exposure, other illnesses, medicines and wider evidence.
Editorial experience
From our work: how we checked this page
For topical-map item O-041, Counterfeit and unauthorised GLP-1-type products was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 6 unique external sources and 9 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Eleni Kiromitis checked study design, biomedical evidence, evidence directness and laboratory context. Dr Stavroula Nikitopoulou checked clinical claims, adverse effects, contraindications, red flags and patient-facing safety wording. Each reviewer stayed within the remit published on the governance page. Yianni Kiromitis retained responsibility for source verification, editorial decisions and correction management.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.